

APPENDIX 3Y – LATE LODGEMENT

On 1 August 2023, 15 January 2024 and 22 January 2025, NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) (“**NeuroScientific**” or “**the Company**”), announced to the ASX the cessation of certain performance shares and options in the capital of the Company. Director, Dr Anton Uvarov, directly held a portion of these performance shares and options, being 1,700,000 options and 450,000 performance shares (together, the **Expired Securities**). The Company has become aware that it failed to lodge an Appendix 3Y after the cessation of the Expired Securities.

Please find attached an Appendix 3Y *Change of Director’s Interest Notice* for Dr Uvarov relating to the cessation of the Expired Securities.

The Company confirms that the late lodgement of the Appendix 3Y for the Director, on each of the occasions was due to an administrative oversight. The Company arranged for the Appendix 3Y to be lodged with ASX as soon as practicable upon the Company becoming aware of the oversight.

The Company and its Directors are aware of their obligations under ASX Listing Rules 3.19A and 3.19B and the Company has procedures in place with its Directors to ensure compliance with ASX Listing Rule 3.19B, including setting out in the appointment letters requirements for disclosures in the change of directors’ interests and standing agenda items discussing changes in personal interests.

The Company confirms that it believes its current arrangements to be adequate to ensure it meets its disclosure obligations under the ASX Listing Rules, including ASX Listing Rule 3.19B, and that failure to do so on these occasions was due to an administrative oversight. However, the Company intends to further review its procedures to identify and implement any potential improvements.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: NeuroScientific Biopharmaceuticals Limited
ACN: 102 832 995

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Anton Uvarov
Date of last notice	25 May 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Ms Yulia Uvarova <TECHINVEST NOMINEES A/C> (Spouse)
Date of change	7 December 2024, 15 January 2024 (options) and 27 July 2023 (performance shares)
No. of securities held prior to change	Ms Yulia Uvarova <Techinvest Nominees A/C> (Spouse) 2,000,000 - Ordinary Shares Anton Uvarov 350,000 – Ordinary Shares 800,000 – Unlisted Options 900,000 – Unlisted Options 150,000 – Performance Shares 150,000 – Performance Shares 150,000 – Performance Shares
Class	Options and performance shares.
Number acquired	-

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	1,700,000 options & 450,000 performance shares.
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	-
No. of securities held after change	Ms Yulia Uvarova <Techinvest Nominees A/C> (Spouse) 2,000,000 - Ordinary Shares Anton Uvarov 350,000 - Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Cessation of options and performance shares as disclosed in the relevant Appendix 3H lodged with ASX on 22 January 2025, 15 January 2024 and 1 August 2023.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/a
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

⁺ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/a
If prior written clearance was provided, on what date was this provided?	N/a

+ See chapter 19 for defined terms.